[go: up one dir, main page]

IN2012DN02736A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02736A
IN2012DN02736A IN2736DEN2012A IN2012DN02736A IN 2012DN02736 A IN2012DN02736 A IN 2012DN02736A IN 2736DEN2012 A IN2736DEN2012 A IN 2736DEN2012A IN 2012DN02736 A IN2012DN02736 A IN 2012DN02736A
Authority
IN
India
Prior art keywords
compounds
toll
vaccine
adjuvants
receptors
Prior art date
Application number
Inventor
Alex Cortez
Yongkai Li
Manmohan Singh
David Skibinski
Tom Yao-Hsiang Wu
Kathy Yue
Xiaoyue Zhang
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of IN2012DN02736A publication Critical patent/IN2012DN02736A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
IN2736DEN2012 2009-09-02 2010-09-01 IN2012DN02736A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23921709P 2009-09-02 2009-09-02
PCT/US2010/047587 WO2011049677A1 (en) 2009-09-02 2010-09-01 Compounds and compositions as tlr activity modulators

Publications (1)

Publication Number Publication Date
IN2012DN02736A true IN2012DN02736A (en) 2015-09-11

Family

ID=43625759

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2736DEN2012 IN2012DN02736A (en) 2009-09-02 2010-09-01

Country Status (27)

Country Link
US (2) US9045470B2 (en)
EP (1) EP2473508B1 (en)
JP (1) JP5525614B2 (en)
CN (1) CN102712636B (en)
AR (1) AR078153A1 (en)
AU (1) AU2010308524B2 (en)
BR (1) BR112012004696B8 (en)
CA (1) CA2772657C (en)
CL (1) CL2012000535A1 (en)
CY (1) CY1119618T1 (en)
DK (1) DK2473508T3 (en)
EA (1) EA020962B1 (en)
ES (1) ES2627669T3 (en)
HR (1) HRP20170707T1 (en)
HU (1) HUE032323T2 (en)
IN (1) IN2012DN02736A (en)
JO (1) JO3257B1 (en)
LT (1) LT2473508T (en)
MX (1) MX2012002654A (en)
PE (1) PE20121156A1 (en)
PL (1) PL2473508T3 (en)
PT (1) PT2473508T (en)
SI (1) SI2473508T1 (en)
SM (1) SMT201700276T1 (en)
TW (1) TWI445708B (en)
UY (1) UY32874A (en)
WO (1) WO2011049677A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
WO2012125942A1 (en) * 2011-03-16 2012-09-20 University Of Medicine And Dentistry Of New Jersey Combination therapy with leukotoxin
UY32306A (en) 2008-12-09 2010-07-30 Gilead Sciences Inc DERIVATIVES OF PTERIDINONE AND PYRIMIDINODIAZEPINONE AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE THE TOLL TYPE RECEIVERS, METHODS AND USES
CN102844047B (en) 2009-09-02 2017-04-05 诺华股份有限公司 Immunogenic composition containing TLR active regulators
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2402028A1 (en) * 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus vaccines for preventing and treating type 1 diabetes (II)
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
CA2804396C (en) 2010-07-06 2021-06-29 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
SI3243526T1 (en) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. RNA delivery to trigger multiple immune pathways
SI2611461T1 (en) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
JP2013544504A (en) 2010-10-11 2013-12-19 ノバルティス アーゲー Antigen delivery platform
TR201811280T4 (en) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Mixed vaccines with low antigen and / or adjuvant doses.
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
CA2840989A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
JP2014525429A (en) * 2011-09-01 2014-09-29 ノバルティス アーゲー Staphylococcus aureus antigen adjuvanted formulation
FI123955B (en) * 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
ES2597755T3 (en) 2012-03-07 2017-01-20 Glaxosmithkline Biologicals Sa Arginine salts of a TLR7 agonist
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822589A1 (en) * 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of rabies virus immunogens
WO2013132041A2 (en) * 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
JP2015524418A (en) 2012-07-27 2015-08-24 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル CD147 as a receptor for pili-mediated adhesion of Neisseria meningitidis to vascular endothelial cells
JP2015528457A (en) * 2012-08-31 2015-09-28 ノバルティス アーゲー Stabilized protein for immunization against STAPHYLOCOCUSAUREUS
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
CN103845731B (en) * 2012-12-05 2015-12-02 复旦大学 Anti-ST2/IL-1R4 antibody is preparing the application prevented and treated in pruritus medicine
JP2016506416A (en) * 2013-01-10 2016-03-03 ノバルティス アーゲー Influenza virus immunogenic compositions and uses thereof
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
CN105828835A (en) 2013-05-10 2016-08-03 诺华股份有限公司 Avoiding narcolepsy risk in flu vaccine
CN104338129B (en) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 Application of Rapamycin as vaccine adjuvant and preparation method thereof
SG11201700070QA (en) 2014-07-11 2017-02-27 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
WO2016044182A1 (en) 2014-09-16 2016-03-24 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US11779603B2 (en) 2016-06-30 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HERV-E reactive T cell receptors and methods of use
EP3511320A4 (en) * 2016-09-09 2020-04-15 Takeda Pharmaceutical Company Limited CYCLIC COMPOUND
AR111760A1 (en) 2017-05-19 2019-08-14 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION
EP3720488A1 (en) 2017-12-04 2020-10-14 Intervet International B.V. Vaccination with replicon particles and oil adjuvant
US10857153B2 (en) * 2018-06-04 2020-12-08 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7287708B2 (en) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like receptor 7 or 8 agonist-cholesterol conjugate and use thereof
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (en) 2019-02-15 2021-09-08 Novartis Ag 3-(1-OXOISOINDOLIN-2-IL)PIPERIDINE-2,6-DIONA SUBSTITUTE DERIVATIVES AND USES THEREOF.
CA3136182A1 (en) * 2019-04-05 2020-10-08 Sumitomo Dainippon Pharma Co., Ltd. Water soluble adjuvant
EP3993888B1 (en) * 2019-07-03 2023-11-22 Merck Patent GmbH Antibody drug conjugate purification
CN114096560B (en) 2019-07-03 2025-06-13 默克专利股份公司 Sugar purification
AU2020407871A1 (en) 2019-12-20 2022-06-30 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof
CN115175937A (en) 2019-12-20 2022-10-11 诺华股份有限公司 Combination of anti-TIM-3 antibody MBG453 and anti-TGF-beta antibody NIS793 with or without decitabine or anti-PD-1 antibody, gabapentin, for the treatment of myelofibrosis and myelodysplastic syndrome
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
JP2023536164A (en) 2020-08-03 2023-08-23 ノバルティス アーゲー Heteroaryl-substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022031011A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Kinetically acting adjuvant ensemble
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
EP4450503A4 (en) * 2021-12-15 2025-12-10 Innovstone Therapeutics Ltd Aromatic heterocyclic compounds, methods for their manufacture and uses thereof
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN119497716A (en) * 2023-06-15 2025-02-21 石药集团中奇制药技术（石家庄）有限公司 A crystal form of ENPP1 inhibitor

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (en) 1978-11-11 1980-05-22 Behringwerke Ag METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
JP2000511769A (en) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション New compound
JP2000512487A (en) 1996-05-14 2000-09-26 スミスクライン・ビーチャム・コーポレイション New compound
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
PT991761E (en) 1997-08-21 2008-04-28 Staat Nl Verteg Door Min Welzi Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
JPH1180156A (en) * 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1- (substituted aryl) alkyl-1H-imidazopyridin-4-amine derivatives
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
WO1999027109A2 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS)
ES2333071T5 (en) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Neisseria meningitidis antigens
WO1999053940A1 (en) 1998-04-23 1999-10-28 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
CN1318103A (en) 1998-07-27 2001-10-17 微生物技术有限公司 Nucleic acids and proteins from streptococcus pneumoniae
EP2053126A1 (en) 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
DE69940404D1 (en) 1998-08-31 2009-03-26 Inhibitex Inc Multicomponent vaccines against Staphylococcus aureus
BR9913311A (en) 1998-08-31 2001-10-16 Trinity College Dublin Isolated nucleic acid molecule, isolated nucleic acid, vector, protein, antibody and antisera formed against a protein, diagnostic kit, processes to reduce coagulase-negative staph infection from a medical retention device, to treat an infection of coagulase-negative staphylococcus, to prevent a coagulase-negative staph infection in a patient, to induce an immune response and to identify compounds that inhibit coagulase-negative staphylococci
NZ511540A (en) 1998-10-09 2004-05-28 Chiron Corp Neisseria genomic sequences and methods of their use
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
EP1140157B1 (en) 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
CN1198932C (en) 1999-03-26 2005-04-27 科特克斯(Om)有限公司 Streptococcus pneumoniae antigens
EP1185297B1 (en) 1999-06-10 2006-05-10 MedImmune, Inc. Streptococcus pneumoniae proteins and vaccines
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
EP1261723B1 (en) 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybrid expression of neisserial proteins
KR20020097200A (en) 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 Identification of essential genes in prokaryotes
US6689369B2 (en) 2000-04-27 2004-02-10 Medimmune, Inc. Immunogenic pneumococcal protein and vaccine compositions thereof
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
US6495079B1 (en) 2000-06-28 2002-12-17 Prisma Fibers, Inc. Process to prepare polymeric fibers with improved color and appearance
DE60139690D1 (en) 2000-07-03 2009-10-08 Novartis Vaccines & Diagnostic IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE
US20040091495A1 (en) 2000-07-20 2004-05-13 Lars Bjorck Protein
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2426738A1 (en) 2000-10-26 2002-05-02 David William Holden Streptococcal genes
CA2425303A1 (en) 2000-10-27 2002-05-02 John Telford Nucleic acids and proteins from streptococcus groups a & b
AT410798B (en) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
CA2447599C (en) 2001-05-18 2015-04-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
AU2002322127B2 (en) 2001-06-15 2008-08-21 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ATE542829T1 (en) 2001-08-02 2012-02-15 Univ Sheffield VACCINE
ES2386386T3 (en) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Immunization against Chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2275127B1 (en) 2002-04-02 2012-09-19 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
JP2006512047A (en) 2002-06-11 2006-04-13 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム Immunogenic composition
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
MY149591A (en) 2002-08-02 2013-09-13 Glaxosmithkline Biolog Sa Vaccines comprising l2 and/or l3 los from neisseria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2504166T3 (en) 2002-09-13 2014-10-08 Novartis Vaccines And Diagnostics, Inc. Group B strep vaccine
DK1549338T3 (en) 2002-10-11 2011-03-28 Novartis Vaccines & Diagnostic Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
EP1615950A2 (en) 2003-04-15 2006-01-18 Intercell AG S. pneumoniae antigens
DE10327439A1 (en) * 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel imidazopyridazinone and imidazopyridone derivatives, their production and their use as pharmaceuticals
CA2526106A1 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
WO2005032582A2 (en) 2003-07-31 2005-04-14 Chiron Corporation Immunogenic compositions for streptococcus pyogenes
CN1918176A (en) 2004-02-18 2007-02-21 默克公司 Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
MX2007003402A (en) 2004-09-22 2007-05-10 Glaxosmithkline Biolog Sa Immunogenic composition for use in vaccination against staphylococcei.
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP1977009B1 (en) 2005-12-27 2016-08-17 Obetech, LLC Adipogenic adenoviruses as a biomarker for disease
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
WO2007116322A2 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
EP2010537B1 (en) * 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
EA015833B1 (en) 2006-03-30 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Immunogenic composition
AR060187A1 (en) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa IMMUNOGENIC COMPOSITION
ES2546213T3 (en) 2008-03-03 2015-09-21 Novartis Ag Compounds and compositions as modulators of TLR activity
CN102762226A (en) * 2009-06-10 2012-10-31 诺华有限公司 Benzonaphthyridine-containing vaccines
CN102760226B (en) * 2011-04-29 2015-07-01 贵州师范大学 Solid square-based test paper objective item answer sheet locating method

Also Published As

Publication number Publication date
CN102712636B (en) 2014-11-05
EA020962B1 (en) 2015-03-31
EP2473508A1 (en) 2012-07-11
CA2772657A1 (en) 2011-04-28
EP2473508B1 (en) 2017-03-08
CY1119618T1 (en) 2018-04-04
BR112012004696B1 (en) 2021-01-05
HUE032323T2 (en) 2017-09-28
CL2012000535A1 (en) 2012-08-17
JP2013503884A (en) 2013-02-04
US20110053893A1 (en) 2011-03-03
PE20121156A1 (en) 2012-08-23
AU2010308524A1 (en) 2012-04-19
ES2627669T3 (en) 2017-07-31
UY32874A (en) 2011-04-29
LT2473508T (en) 2017-06-12
EA201200406A1 (en) 2012-09-28
AR078153A1 (en) 2011-10-19
CA2772657C (en) 2015-11-24
JO3257B1 (en) 2018-09-16
BR112012004696B8 (en) 2021-05-25
US9045470B2 (en) 2015-06-02
PL2473508T3 (en) 2017-08-31
AU2010308524B2 (en) 2014-03-20
BR112012004696A2 (en) 2017-05-23
HRP20170707T1 (en) 2017-07-14
PT2473508T (en) 2017-05-29
JP5525614B2 (en) 2014-06-18
CN102712636A (en) 2012-10-03
SI2473508T1 (en) 2017-07-31
TW201113281A (en) 2011-04-16
WO2011049677A1 (en) 2011-04-28
SMT201700276T1 (en) 2017-07-18
TWI445708B (en) 2014-07-21
MX2012002654A (en) 2012-03-26
US20150225432A1 (en) 2015-08-13
DK2473508T3 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
IN2012DN02736A (en)
SG178954A1 (en) Immunogenic compositions including tlr activity modulators
JO3065B1 (en) Compounds and compositions as tlr activity modulators
MX341395B (en) Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX344238B (en) Tetrazole compounds and methods of making and using same.
MX347471B (en) Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules.
UA115983C2 (en) Dna-pk inhibitors
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
MX343687B (en) Tricyclic sulfonamide compounds and methods of making and using same.
MX375202B (en) NOVEL ADJUVANT COMPOSITIONS.
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
MX2011011618A (en) Therapeutic agents 713.
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
BR112013023354A2 (en) equine rhinitis vaccine
EA201291384A1 (en) THERAPEUTIC AGENTS 976
TH158461A (en) Compounds and constituents as TLR modifiers
TN2010000338A1 (en) Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant
MX361456B (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease.
UA97289C2 (en) Compounds and compositions thereof as grp119 activity modulators